

Amalia (Meier) Magaret, PhD

CONTACT INFORMATION

Address: Department of Pediatrics, University of Washington,
Box 359300, Seattle, WA 98195
Phone: (206) 884-1019
Email: amag@uw.edu

1. PERSONAL DATA

Place of Birth: Maryville, Missouri, USA

2. EDUCATION

1992 BS in Chemistry/Math, University of Notre Dame
1997 MS in Applied Statistics, Western Michigan University
2001 PhD in Biostatistics, University of Washington

3. POST GRADUATE TRAINING

1998-00 Statistician, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA
1998-05 Statistician and Consultant, University of Washington research projects at Kenyatta National Hospital, Nairobi, Kenya
2000-01 Pre-Doctoral Fellow, Center for AIDS/STD Research, Seattle, WA
2002-03 Post-Doctoral Research Associate, SCHARP, Fred Hutchinson Cancer Research Center, Seattle, WA
2003-04 Clinical Research Associate, Infectious Diseases Fred Hutchinson Cancer Research Center, Seattle, WA

4. FACULTY POSITIONS HELD

2004-10 Research Assistant Professor, Laboratory Medicine, UW
2004-10 Joint Assistant Member, Biostatistics, FHCRC
2004+ Member of the Graduate Faculty, UW
2010-2016 Research Associate Professor, Laboratory Medicine, UW
2013-2016 Adjunct Res. Associate Professor, Department of Biostatistics, UW
2010-2018 Joint Associate Member, VID D and Biostatistics, FHCRC
2016-2019 Research Professor, Laboratory Medicine, UW
2016+ Adjunct Research Professor, Department of Biostatistics, UW
2018+ Affiliate Member, VID D and Biostatistics, FHCRC
2019+ Research Professor, Pediatrics, UW

5. HOSPITAL POSITIONS HELD N/A

6. CURRENT (NON-UW) EMPLOYMENT N/A

7. HONORS

1997 ASA Award for Outstanding Achievement, Western Michigan University
2001 Outstanding Student in Biostatistics, SPHCM, University of Washington

8. BOARD CERTIFICATION N/A**9. CURRENT LICENSE TO PRACTICE N/A****10. DIVERSITY, EQUITY AND INCLUSION ACTIVITIES**

| Year | Title | Institution | Role |
|---------------------------------|----------------------------------|---------------------------------|-------------|
| Teaching and education | | | |
| 2021-23 | Summer Scholar's Internship | Seattle Children's Research In. | Mentor |
| 2022-24 | Summer Scholar's Boot Camp | Seattle Children's Research In. | Instructor |
| Research and Scholarship | | | |
| 2021-23 | CFRD and race study | UW and Gallaudet University | Researcher |
| 2022-24 | Race and study participation | UW | Researcher |
| 2023-24 | Health Equity Team Science Award | Cystic Fibrosis Foundation | Reviewer |
| Professional Activity | | | |
| 2021-24 | Research Anti-Racism Committee | Seattle Children's Research In. | Member |
| 2022-24 | White Accountability Group | UW School of Public Health | Facilitator |
| 2024+ | Bias Reduction in Medicine | UW Department of Pediatrics | Facilitator |

11. PROFESSIONAL ORGANIZATIONS

2001+ American Statistical Association

2001+ International Biometric Society (Western North American Region)

12. TEACHING RESPONSIBILITIES

Table 1. School of Public Health courses taught

| Course | Title | Credits | Years | Students | Responsibility |
|------------------|---------------------------------------|---------|--------------|----------|----------------|
| Biost 310 | Biostatistics for the Health Sciences | 3 | 2015 | 94 | All lectures |
| Epi 590 | Vaccines | 3 | 2006 to 2018 | 50 | 1 lecture |
| Early Fall Start | 'CIS Seattle' | N/A | 2012 | 40 | 1 lecture |
| Biost 572 | Current Issues in Clinical Trials | 3 | 2021 | 10 | 1 lecture |

Table 2. UW Mentoring responsibilities (last 5 years)

| Year | Role | Student | Department |
|------|------------------------------------|----------------|---------------|
| 2019 | Mentor, research assistantship | Mark Warden | Epidemiology |
| 2019 | Mentor, independent study | Kun Yue | Biostatistics |
| 2021 | GSR, Dissertation committee | Subodh Selukar | Biostatistics |
| 2023 | Mentor, research assistantship | Ellen Graham | Biostatistics |
| 2024 | Member, PhD Dissertation committee | Mark Warden | Epidemiology |

Table 3. Seattle Children's Research Institute teaching and mentoring

| Event | Title | Year | Student | Responsibility |
|---|---|-----------|---------------|----------------|
| TDNCC journal club | Statistics in cystic fibrosis research | 2019+ | ~12 staff | 2 hrs monthly |
| Underrepresented minority intership mentoring | Intersection of race and diabetes in CF | 2021-2023 | Blessed Mbogo | 50 hours |
| Summer Scholars Program | Using math to prevent HIV | 2022+ | 50 scholars | 2 hours |

Table 4. Community service teaching and mentoring

| Event | Title | Years | Students | Responsibility |
|--|---------------------------|-----------|----------|---------------------------|
| Expand Your Horizons, STEM at Edmonds Community College | Using math to prevent HIV | 2013 | 40 | 1 lecture |
| Senior Capstone Project, Gallaudet University, Washington D.C. | Risk scores and AEs | 2023-2024 | 1 | Weekly mentoring meetings |

13. EDITORIAL RESPONSIBILITIES

None

14. SPECIAL NATIONAL RESPONSIBILITIES

1992-1994 United States Peace Corps volunteer, Gabon, West Africa
 Taught math and science at the junior high level, in French

2006-8 Grant reviewer for Pennsylvania State Department of Health

2009 Grant reviewer for Bill and Melinda Gates Foundation

2017 Grant reviewer for National Institutes of Allergy and Infectious Disease, NIH, T-cell reagent research for the study of allergic diseases (U19)

2019+ Grant reviewer and Mentor for Cystic Fibrosis Foundation, Clinical Scholars Program

2019+ Reviewer for Cystic Fibrosis Foundation, Physicians Training Program

2019+ Mentor, Cystic Fibrosis Foundation Statistics Network Program

2019+ Reviewer, Cystic Fibrosis Reproductive and Sexual Health Collaborative PCOR training program

2022+ Member, Protocol Review Committee, Cystic Fibrosis Foundation

2023+ Reviewer, Health Equity Team Science Award, Cystic Fibrosis Foundation

15. SPECIAL LOCAL RESPONSIBILITIES

2005-11 Institutional Review Board, Cancer Research and Biostatistics, Seattle WA

2013-18 Member, Admissions Committee, Department of Biostatistics

2014-19 Member, Grand Rounds Committee, Department of Lab Medicine

2016-19 Member, Appointments and Promotions Committee, Dept of Lab Medicine

2018-21 Member, Appointments and Promotions Committee, School of Medicine

2020-24 DSMB statistician, SPARC and MHAPPS trials, Boise, ID

2020-24 Member, Seattle Children's Research Institute Anti-Racism Committee

2022+ Facilitator, UW School of Public Health White Accountability Group

2022 Member, Admissions Committee, Department of Biostatistics

2024+ Facilitator, UW School of Medicine, Bias Reduction in Medicine

16. RESEARCH FUNDING**Active funding**

MAGAR21A0-P Magaret (PI) 1/1/2021-12/31/2027

Cystic Fibrosis Foundation: Role: Principal Investigator

A Prospective Study to Evaluate Maternal and Fetal Outcomes in the Era of Modulators (MAYFLOWERS)

This award is for a prospective study to prospectively follow women with CF during and after pregnancy to assess maternal outcomes, perception of pregnancy, and impact of CFTR modulators.

GOSS22Y0 Goss (PI) 4/1/2003-3/31/2025

Cystic Fibrosis Foundation: Role: Faculty Director, Statistical Research

Therapeutics Development Network Coordinating Center

This award is to manage the data coordinating center for adult CF trials originating from the Seattle site.

NICHOL18Y3 Nichols (PI) 4/1/2018-3/31/2024

Cystic Fibrosis Foundation: Role: Faculty Biostatistician

Clinical Research Scholars Program Award for TDNCC

This award provides infrastructure for clinical research career development across the network, research network development, network training, and consulting with outside sponsors interested in CF.

R01FD006848 Goss (PI) 8/15/2020-6/30/2025

Food and Drug Administration: Role: Faculty Biostatistician

Gallium-NTM: A Phase 1b, Multi-Center Study of IV Gallium Nitrate in Patients with CF Who are Colonized with Nontuberculosis Mycobacterium (ABATE)

This award is for a prospective, multicenter, nonrandomized, open-label study to investigate the safety and antimycobacterial effect of two 5-day infusions of IV gallium in adults with CF who are colonized with NTM.

BEGIN-HELTSH20K0 Heltshe (PI) 1/1/2020-12/31/2026

Cystic Fibrosis Foundation: Role: Faculty Biostatistician

A Prospective Study to Evaluate Effects of Corrected CFTR Function (BEGIN)

This award is for a prospective study to evaluate effects of corrected CFTR function specifically improvements in growth, gastrointestinal health and pulmonary function.

BEGINNING-WOODS21K0 Woods (PI) 8/1/2021-7/31/2024

Cystic Fibrosis Foundation: Role: Faculty Biostatistician

BEGIN Novel Imaging Biomarkers (BEGINNING)

The overarching goal of this study is to define the role of structural and functional MR imaging in 3-5 year old children with CF to facilitate future CF research studies.

NTM-HAMBLE22Ko Hamblett(PI) 6/1/2022-5/31/2026

Cystic Fibrosis Foundation: Role: Faculty Biostatistician

Prospective Evaluation of a Standardized Approach to Diagnosis & Treatment of Nontuberculous Mycobacteria Disease in CF (PREDICT-PATIENCE)

The study will help define a standardized approach to the diagnosis and treatment of NTM pulmonary disease, define response to treatment, and collect relevant data associated with the diagnosis and treatment of NTM disease to build a framework for true therapeutic trials in the future.

Pending funding

Heltshe(PI)

Cystic Fibrosis Foundation: Role: Faculty Biostatistician

Clinical Research Scholars Award (CRSP)

This award provides infrastructure for clinical research career development across the network, research network development, network training, and consulting with outside sponsors interested in CF

Heltshe(PI)

Cystic Fibrosis Foundation: Role: Faculty Biostatistician

Statistical methods to support inclusion of historical controls on CF clinical trials (REACH-Stat methods)

Our goal is to advance the development of new treatments in among persons who either cannot take or cannot tolerate current modulators. We will 1) determine the best way to use external data, 2) expand the set of useable external data by doing analyses on existing trial and registry data, and 3) set up a system to share data with future companies and researchers while protecting privacy.

(Selected) Completed funding

UW Center for AIDS and STD Research Fellowship

01/01/00 - 12/20/01

P01 AI30731-23

(A. Wald)

7/1/2013-6/30/2018

NIH / NIAID: Role: Core Leader; Statistical Core

Clinical Epidemiology & Pathogenesis of Asymptomatic Genital Herpes (Core C)

This Core of the P01 grant has four specific aims: 1) consult in the design of experimental methods, including sample size computation, and the conceptualization of viral dynamics studies, 2) coordinate data management, overseeing data collection procedures, laboratory sample management, results handling and integration of diverse data sources, 3) perform appropriate statistical analyses and modeling, contributing to the interpretation and reporting of results, 4) design novel dynamical mathematical models and other statistical methodologies as needed, optimizing our analytic approach.

Grant 26469

(Celum, PI)

05/01/03 - 4/01/09

Bill & Melinda Gates Foundation: Role: Co-investigator, Statistical Manager

HSV-2 Suppression to Prevent HIV Transmission

To conduct a multi-site randomized trial in Africa and Asia to assess the efficacy of acyclovir treatment on the sexual transmission of HIV in HIV-serodiscordant couples.

RO1 CA 213130-01 (M. Madeleine)

2/22/2017-08/21/2020

FHCRC/NIH: Role: Co-investigator

Therapeutic use of HPV L1 vaccine in anogenital neoplasia: VIVA Trial

We will conduct a randomized, double-blind, placebo-controlled proof-of-concept clinical trial of quadrivalent HPV vaccine administered to women and men with high-grade intraepithelial vulvar or anal neoplasia, or Stage 1 vulvar or anal cancer.

U19 AI 113173-02 (Marrazzo)

07/01/2014-06/30/2019

NIH: Role: Co-investigator

UW STI CRC: The Genital Microbiome as a Determinant of Sexual Health & Local Immunity

Our objective is to establish a Sexually Transmitted Infection (STI) Cooperative Research Center at the University of Washington (UW) to investigate interactions between the human genital microbiome and syndromes and pathogens that contribute to STI-related morbidity. We will apply our innovative approach of intensive sampling and robust characterization of the genital microbiome to investigation of STI pathogens and bacterial communities.

5U01HL114623-05 Hamblett (PI)

9/1/2013-6/30/2021

NIH/NHLBI: Role: Biostatistician

Optimizing Treatment for Early Pseudomonas aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter Randomized Trial- Data Coordinating Center

The objectives of this multicenter, randomized study are to evaluate the effectiveness of azithromycin therapy on the treatment of new onset Pseudomonas aeruginosa in children with cystic fibrosis.

MAGARE19Ko

Magaret(PI)

2/1/2019-4/30/2020

Cystic Fibrosis Foundation: Role: PD/PI

Bedaquiline for M. abscessus lung infection (BDQ)

This is a planning grant to finalize a clinical trial protocol, focusing on the potential benefits of management of pulmonary infection due to *M. abscessus* in CF patients. The planning grant is to develop a well-established paradigm for clinical trial design, which is currently a critical barrier to developing NTM therapeutics.

17. BIBLIOGRAPHY**a) Manuscripts in Refereed Journals**

1. Eschenbach D, Thwin SS, Patton D, Hooten T, Stapleton A, Agnew K, Winter K, **Meier A**, Stamm W. 2000. Influence of the normal menstrual cycle on vaginal tissue, discharge and microflora. Clin Infect Dis;30(6):901-7.

2. Eschenbach DA, Patton DL, **Meier AS**, Thwinn SS, Aura J, Stapleton A, Hooton TM. 2000. Effects of oral contraception pill use on vaginal flora and vaginal epithelium. *Contraception*; 62(3):107-12.
3. Miller L, Patton D, **Meier A**, Thwin SS, Hooten TM, Aura J, Agnew K, Stapleton A, Eschenbach D. 2000. Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. *Obstet Gynecol*;96(3):431-9.
4. Patton DL, Thwin SS, **Meier A**, Hooton TM, Stapleton AE, Eschenbach DA. 2000. Epithelial cell layer thickness and immune cell populations in the normal human vagina at different stages of the menstrual cycle. *Am J Obstet Gynecol*;183(4):967-73.
5. Eschenbach DA, Patton DL, Hooton TM, **Meier AS**, Stapleton A, Aura J, Agnew K. Effects of vaginal intercourse with and without a condom on vaginal flora and vaginal epithelium. 2001. *J Infect Dis*;183(6):913-8.
6. Van Kessel K, Reed S, Newton K, **Meier A**, Lentz G. 2001. The second stage of labor and stress urinary incontinence. *Am J Obstet Gynecol*;184(7):1571-5.
7. Mwachari C, Cohen CR, **Meier A**, Nganga L, Kimari J, Odhiambo J. 2001. Respiratory tract infection in HIV-1 infected adults in Nairobi, Kenya: evaluation of risk factors and the WHO treatment algorithm. *J Acquir Immune Defic Syndr*;27(4):365-71.
8. Penner JA, **Meier AS**, Mwachari C, Ayuka F, Muchina B, Odhiambo J, Cohen CR. 2003. Risk factors for pneumonia in urban-dwelling HIV-1 infected women: A case control study in Nairobi, Kenya. *J Acquir Immune Defic Syndr*;32(2):223-28.
9. Mwachari CW, **Meier AS**, Muyodi J, Gatei W, Waiyaki P, Cohen CR. 2003. Chronic diarrhoea in HIV-1-infected adults in Nairobi, Kenya: evaluation of risk factors and the WHO treatment algorithm. *AIDS*;17(14):2124-2126.
10. Criniti A, Mwachari CW, **Meier AS**, Nduba V, Sanguli L, Ngumo JK, Cohen CR. 2003. Association of hormonal contraception and HIV-seroprevalence in Nairobi, Kenya. *AIDS*;17(18):2667-9.
11. **Meier AS**, Richardson BA, Hughes JP. 2003. Discrete proportional hazards models for mismeasured outcomes. *Biometrics*;59:947-54.
12. Zerr DM, **Meier AS**, Selke SS, Frenkel LM, Huang ML, Wald A, Rhoads MP, Nguy L, Bornemann R, Morrow RA, Corey L. 2005 A population-based study of primary human herpesvirus 6 infection. *N Engl J Med*;352(8):768-76.
13. Meyer JL, Crosby RA, Whittington WL, Carrell D, Ashley-Morrow R, **Meier AS**, Harrington RD, Diclemente R, Wald A. The psychosocial impact of serological herpes simplex type 2 testing in an urban HIV clinic. *Sex Transm Infect*. 2005 Aug;81(4):309-15.
14. Cohen CR, Koochesfahani KM, **Meier AS**, Shen C, Karunakaran K, Ondondo B, Kinyari T, Mugo NR, Nguti R, Brunham RC. 2005. Immunoepidemiologic profile of chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon- gamma. *J Infect Dis*;192(4):591-9.
15. **Meier AS**, Gilbert PB. 2005. Accuracy and precision of estimating intervention efficacy when the timing of observed events differ by treatment arm. *Contemp Clin Trials*;26(5):598-610.

16. Morrow RA, Friedrich BS, **Meier AS**, Corey L. 2005. Use of *biokit* HSV-2 rapid assay to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. *BMC Infectious Diseases*;5:84.
17. Fredricks DN, Smith C, **Meier AS**. 2005. Comparison of six DNA extraction methods for recovery of fungal DNA as assessed by quantitative PCR. *J Clin Microbiol*;43(10):5122-8.
18. Bukusi EA, Cohen CR, **Meier AS**, Waiyaki, PW, Nguti R, Njeri JN, Holmes KK. 2006. Bacterial vaginosis: risk factors among women and their male partners. *Sex Transm Dis*;33(6):361-7.
19. Mugo NR, Kiehlbaugh JA, Nguti R, **Meier A**, Gichuhi WJ, Stamm WE, Cohen CR. 2006. Effect of HIV-1 infection on treatment outcome of acute salpingitis. *Obstet Gynecol*;107(4):807-12.
20. Mwachari CW, Nduba VN, Park DR, **Meier AS**, Kariuki JN, Muyodi JA, Kigo A, Holmes KK, Cohen CR. 2006. Clinical presentation and prognostic indicators among HIV-infected and non-infected adults with community acquired pneumonia in Nairobi. *Int J Tuberc Lung Dis*;10(5):516-22.
21. Hosken N, McGowan P, **Meier A**, Koelle DM, Sleath P, Wegener F, Elliott M, Grabstein K, Posavad C, Corey L. 2006. The diversity of the CD8+ T cell response to HSV-2 proteins among persons with genital herpes. *J Virol*;80(11):5509-15.
22. Casper C, Carrell D, Miller KG, Judson FD, **Meier AS**, Pauk JS, Morrow RA, Corey L, Wald A, Celum C. 2006. HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study. *Sex Transm Infect*;82(3):229-35.
23. Kim NH, **Meier A**, Huang ML, Kuntz S, Selke S, Celum C, Corey L, Wald A. 2006. Oral herpes simplex virus type 2 (HSV-2) reactivation in HIV-positive and HIV-negative men. *J Infect Dis*;194(4):420-7.
24. **Meier AS**, Bukusi EA, Cohen CR, Holmes KK. 2006. Independent association of hygiene, socioeconomic status, and circumcision with reduced risk of HIV infection among Kenyan men. *J Acquir Immune Defic Syndr*;43(1):117-118.
25. Casper C, **Meier AS**, Wald A, Morrow RA, Corey L, Moscicki AB. 2006. Human herpesvirus 8 infection among adolescents in the REACH cohort. *Arch Pediatr Adolesc Med*;160(9):937-42.
26. Cohen CR, Nosek M, **Meier AS**, Astete SG, Mugo NR, Totten PA. 2007. Risk Factors for *Mycoplasma genitalium* in a prospective cohort study of female sex workers in Nairobi, Kenya. *Sexually Transmitted Diseases*;34(5):274-279.
27. Rhoads MP, **Magaret AS**, Zerr DM. 2007. Family saliva sharing behaviors and age of human herpesvirus-6B infection. *Journal of Infection*;54:623-26.
28. **Magaret AS**, Wald A, Huang ML, Selke S, Corey L. 2007. Optimizing PCR positivity criterion for detection of HSV DNA on skin and mucosa. *Journal of Clinical Microbiology*;45(5): 1618-20.
29. Bochud PY, **Magaret AS**, Koelle DM, Aderem A, Wald A. 2007. Polymorphisms in *toll-like receptor 2* are associated with increased viral shedding and lesion rate in patients with genital herpes simplex virus Type 2 infection. *J Infect Dis*;196(4):505-9.

30. Mark KE, Corey L, Meng TC, **Magaret AS**, Huang ML, Selke S, Liu P, Tyring S, Warren T, Sacks S, Leone P, Bergland V, Wald A. 2007. Topical resiquimod 0.01% gel decreases HSV-2 genital shedding: a randomized controlled trial. *J Infect Dis*;195(9):1324-31.
31. Zuckerman RA, Lucchetti A, Whittington WLH, Sanchez J, Coombs RW, Zuniga R, **Magaret AS**, Wald A, Corey L, Celum C. 2007. HSV suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1, HSV-2 seropositive men: a randomized, double-blind, placebo-controlled crossover trial. *J Infect Dis*;196(10):1500-1508.
32. Richards J, Scholes D, Caka S, Drolette L, **Magaret AS**, Yarbro P, Lafferty W, Crosby R, Diclemente R, Wald A. 2007. HSV-2 serologic testing in an HMO population: uptake and psychosocial sequelae. *Sex Transm Dis*;34(9):718-25.
33. Gardella C, Barnes J, **Magaret AS**, Richards J, Drolette L, Wald A. 2007. Prenatal herpes simplex virus serologic screening beliefs and practices among obstetricians. *Obstet Gynecol*;110(6):1364-70.
34. Lingappa JR, Lambdin B, Bukusi E, Ngure K, Kavuma L, Mubiana I, Kanweka W, Allen S, Kiarie JN, Makhema J, Were E, Manongi R, Coetsee D, de Bryun G, Delany-Moretlwe S, **Magaret A**, Mugo N, Mujugira A, Ndase P, Celum C. 2008. Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial. *PLoS One*;3(1):e1411.
35. Abu-Raddad LJ, **Magaret AS**, Celum C, Wald A, Morris M, Longini IM, Self S, Corey L. 2008. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. *PLoS One*;3(5):e2230.
36. Nguyen HQ, **Magaret AS**, Kitahata MM, Van Rompaey SE, Wald A, Casper C. 2008. Persistent Kaposi Sarcoma in the era of HAART: characterizing the predictors of clinical response. *AIDS*;22(8):937-45.
37. **Magaret AS**. 2008. Incorporating validation subsets into discrete proportional hazards models for mismeasured outcomes. *Statistics in Medicine*;27(26):5456-70.
38. Koelle DM, **Magaret A**, McClurkan CL, Remington ML, Warren T, Teofilovici F, Wald A. 2008. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve or HSV-2-infected subjects. *Clinical and Vaccine Immunology*;15(5):773-82.
39. Nduba VN, Mwachari CW, **Magaret AS**, Park DR, Kigo A, Hooten TM, Cohen CR. 2008. Placebo found equivalent to amoxicillin for treatment of acute bronchitis in Nairobi, Kenya: a triple-blind randomized equivalence trial. *Thorax*;63(11):999-1005.
40. Mark KE, Wald A, **Magaret AS**, Selke S, Olin L, Huang ML, Corey L. 2008. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. *J Infect Dis*;198(8):1141-9.
41. Johnston C, **Magaret A**, Selke S, Remington M, Corey L, Wald A. 2008. Herpes simplex virus viremia during primary genital infection. *J Infect Dis*;198(1):31-4.
42. Gardella C, Goltra LB, Laschansky E, Drolette L, **Magaret A**, Chadwick HS, Eschenbach D. 2008. High-concentration supplemental perioperative oxygen to reduce the incidence of postcesarean surgical site infection: a randomized controlled trial. *Obstet Gynecol*;112(3):545-52.

43. Baeten J, Strick L, Lucchetti A, Whittington W, Sanchez J, Coombs R, **Magaret A**, Wald A, Corey L, Celum C. 2008. Herpes simplex virus suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 co-infected women: a randomized, placebo-controlled, cross-over trial. *J Infect Dis*;98(12):1804-8.
44. Zuckerman RA, Lucchetti A, Whittington WL, Sánchez J, Coombs RW, **Magaret A**, Wald A, Corey L, Celum C. 2009. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. *AIDS*;23(4):479-83.
45. **Magaret AS**, Johnston C, Wald A. 2009. Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. *STI*;85(4):270-5.
46. Lingappa JR, Kahle E, Mugo N, Mujugira A, **Magaret A**, Baeten J, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife K, Debruyn G, Gray G, McIntyre J, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Coombs RW, Morrow R, Whittington W, Corey L, Wald A, Celum C; Partners HSV-2/HIV-1 Transmission Study Team. 2009. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. *PLoS ONE*;4(4):e5272. Epub.
47. Martin ET, Krantz E, Gottlieb SL, **Magaret AS**, Langenberg A, Stanberry L, Kamb M,, Wald A. 2009. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. *Arch Intern Med*;169(13):1233-40.
48. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, Remington M, **Magaret A**, Koelle DM, Wald A, Corey L. 2009. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. *Nature Medicine*;15(8):886-92.
49. Martin ET, Taylor J, Kuypers J, **Magaret A**, Wald A, Zerr D, Englund JA. 2009. Detection of Bocavirus in saliva of children with and without respiratory illness. *Journal of Clinical Microbiology*, 47:4131-4132.
50. Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, **Magaret A**, Wald A, Corey L. 2009. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. *Science Translational Medicine* 1, 7ra16.
51. Celum C, Wald A, Lingappa JR, **Magaret AS**, Wang RS, Mugo N, Mujugira A, Baeten JM, Mullins JI, Hughes JP, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Stevens W, Campbell MS, Thomas KK, Coombs RW, Morrow R, Whittington WL, McElrath MJ, Barnes L, Ridzon R, Corey L; the Partners in Prevention HSV/HIV Transmission study team. 2010. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. *N Engl J Med*; 362(5):427-39.
52. Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, **Magaret AS**, Wang RS, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C; for the Partners in Prevention HSV/HIV Transmission Study Team. 2010. Daily aciclovir for

- HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. *Lancet*;375(9717):824-33.
53. Tata S, Johnston C, Huang ML, Selke S, **Magaret A**, Corey L, Wald A. 2010. Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. *J Infect Dis*; 201(4):499-504.
 54. Posavad CM, Remington M, Mueller DE, Zhao L, **Magaret AS**, Wald A, Corey L. 2010. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. *J Immunol*;184(6):3250-9.
 55. Gardella C, Huang ML, Wald A, **Magaret A**, Selke S, Morrow R, Corey L. 2010. Rapid PCR assay to detect herpes simplex virus in the genital tract of women in labor. *Obstet Gynecol*; 115(6):1209-16.
 56. Martin ET, Fairchok MP, Kuypers J, **Magaret A**, Zerr DM, Wald A, Englund JA. 2010. Frequent and prolonged shedding of bocavirus in young children attending daycare. *J Infect Dis*;201(11):1625-32.
 57. Koelle DM, **Magaret A**, Warren T, Schellenberg GD, Wald A. 2010. *APOE* genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. *Sex Transm Infect*;86(3):202-6.
 58. Laing KJ, **Magaret AS**, Mueller DE, Zhao L, Johnston C, DeRosa SC, Koelle D, Wald A, Corey L. 2010. Diversity in CD8+ T-cell epitope breadth and function among persons with genital herpes. *J Clin Immunology*, 30(5):703-22.
 59. Mark KE, Wald A, **Magaret AS**, Selke S, Kuntz S, Huang ML, Corey C. 2010. Rapidly clearing episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults. *J Acquir Immune Defic Syndr*;54:482-488.
 60. Lingappa J, Nakku-Joloba E, **Magaret A**, Friedrich D, Dragavon J, Kambugu F, Joloba M, Whalen C, Coombs R, Celum C, Morrow RA. 2010. Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans. *Int J STD and AIDS*;21:611-616.
 61. Phipps W, Saracino M, **Magaret A**, Selke S, Remington M, Huang ML, Warren T, Casper C, Corey L, Wald A. 2011. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. *J Infect Dis*;203:180-187.
 62. Curlin ME, Cassis-Ghavami F, **Magaret A**, Spies G, Duerr A, Celum C, Sanchez J, Margolick J, Detels R, McElrath J, Corey L. 2011. Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection. *AIDS*;25(2):153-158.
 63. Bateganya MH, Stanaway J, Brentlinger PE, **Magaret AS**, Wald A, Jackson O, Casper C. 2011. Predictors of survival after a diagnosis of non-hodgkin's lymphoma in a resource-limited setting: a retrospective study on the impact of HIV infection and its treatment. *J Acquir Immune Defic Syndr*;56(4):312-9.
 64. Tronstein E, Johnston C, Huang ML, Selke S, **Magaret A**, Warren T, Corey L, Wald A. 2011. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. *JAMA*;305(14):1441-9.
 65. Schiffer JT, Wald A, Selke S, Corey L, **Magaret A**. 2011. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. *J Infect Dis*;204(4):554-61.

66. Butler-Wu SM, Burns EM, Pottinger PS, **Magaret AS**, Rakeman JR, Matsen III FA and Cookson BT. 2011. Optimization of periprosthetic culture for the diagnosis of propionibacterium *acnes* prosthetic joint infection. *J Clin Micro*;49(7):2490-5.
67. Mujugira A, **Magaret A**, Baeten J, Celum C, Lingappa J for the Partners in Prevention HSV/HIV transmission study team. 2011. Risk factors for HSV-2 infection among sexual partners of HSV-2/HIV-1 co-infected persons. *BMC Research Notes*;4:64.
68. Strachan E, Saracino M, Selke S, **Magaret A**, Buchwald D, Wald A. 2011. The Effects of Daily Distress and Personality on Genital HSV Shedding and Lesions in a Randomized, Double-blind, Placebo-Controlled, Crossover Trial of Acyclovir in HSV-2 Seropositive Women. *Brain Behav Immun*;25(7):1475-81.
69. Posavad C, **Magaret AS**, Mueller DE, Zhao L, Laing K, Wald A, Corey L. 2011. Development of an interferon- γ elispot assay to detect human HSV-2 peptide-specific T-cell responses. *Vaccine*;29(40):7058-7066.
70. Schiffer JT, **Magaret A**, Selke S, Corey L, Wald A. 2011. Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. *J Antimicro Chemo*;66(11):2593-600.
71. **Magaret AS**, Stanaway J. 2011. Sample size for a binomial proportion with autocorrelation. *Stat Comm Infect Dis*;3(1):Article 8. DOI: 10.2202/1948-4690.1036.
72. Cattamanchi A, Saracino M, Selke S, Huang ML, **Magaret A**, Celum C, Corey L, Wald A, Casper C. 2011. Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men. *J Med Virol*;83(10):1696-703.
73. Hughes JP, Baeten JM, Lingappa JR, **Magaret AS**, Wald A, deBruyn G, Kiarie J, Inambao M, Kilembe W, Farquhar C, Celum C, for the Partners in Prevention HSV/HIV Transmission Study Team. 2012. Determinants of per coital act HIV-1 infectivity among African HIV-1 serodiscordant couples. *J Infect Dis*;205(3):358-65.
74. Johnston C, Saracino M, Kuntz S, **Magaret AS**, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, and Wald A. 2012. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. *Lancet*;379(9816):641-7.
75. Stanaway J, **Magaret AS**, Martin ET, Gottlieb SL, Wald A. 2012. Case-crossover analysis of condom use and HSV-2 acquisition. *Sex Transm Dis*;39(5):388-93.
76. Moss N, **Magaret A**, Laing KJ, Kask AS, Wang M, Mark KE, Schiffer JT, Wald A, Koelle D. 2012. Peripheral blood CD4 T-cell and pDC reactivity to HSV-2 and pDC number do not correlate with the clinical or virologic severity of recurrent genital herpes. *J Virol*;86(18):9952-63.
77. de Bruyn G, **Magaret A**, Baeten JM, Lingappa J, Ndase P, Celum C, Wald A. 2012. Mortality in Members of HIV-1 serodiscordant couples in Africa: results of analyses from a multicenter randomized trial. *BMC Infect Dis*;12(1):277.
78. Schiffer JT, Swan D, Al Sallaq R, **Magaret A**, Johnston C, Mark KE, Selke S, Ocbamichael N, Kuntz S, Zhu J, Robinson B, Huang ML, Jerome K, Wald A, Corey L. 2013. Rapid localized and immunologic containment define herpes simplex virus-2 reactivation in the human genital tract. *ELife*;2:e00288.

79. Mujugira A, **Magaret A**, Celum C, Wald A. 2013. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission of from HSV-2/HIV-1 co-infected persons: a randomized controlled trial. Mujugira A, Magaret AS, Celum C, Baeten JM, Lingappa JR, Morrow RA, Fife KH, Delany-Moretlwe S, de Bruyn G, Bukusi EA, Karita E, Kapiga S, Corey L, Wald A; for the Partners in Prevention HSV/HIV Transmission Study Team. *J Infect Dis*;208(9):1366-74.
80. Wald A, Selke S, **Magaret A**, Boeckh M. 2013. Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults. *J Med Vir*;85(9):1557-60.
81. Perti T, Saracino M, Baeten JM, Johnston C, Diem K, Ochbami Michael N, Huang ML, Selke S, **Magaret A**, Corey L, Wald A. 2013. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in HIV-1, HSV-2 positive persons: a randomized, crossover trial. *J Acquir Immune Defic Syndr*;63(2):201-8.
82. Chu HY, Kuypers J, Renaud C, Wald A, Martin E, Fairchok M, **Magaret A**, Saracino M, Englund JA. 2013. Molecular epidemiology of respiratory syncytial virus transmission in childcare. *J Clin Vir*;57(4):343-50.
83. Limaye A, Hayes TS, Huang ML, **Magaret A**, Boeckh M, Jerome K. 2013. Quantitation of cytomegalovirus DNA load in dried blood spots correlates well with plasma viral load. *J Clin Micro*;51(7):2360-4.
84. Gantt S, Huang ML, **Magaret A**, Bunts L, Selke S, Wald A, Corey L, Rosenthal PJ, Dorsey G, Casper C. 2013. An artesunate-containing antimalarial treatment did not suppress cytomegalovirus viremia. *J Clin Vir*;58(1):276-8.
85. Jacob ST, Pavlinac PB, Nakiyingi L, Banura P, Baeten JM, Morgan K, **Magaret A**, Manabe Y, Reynolds SJ, Liles WC, Wald A, Joloba ML, Mayanja-Kizza H, Scheld WM. 2013. Mycobacterium tuberculosis bacteremia in a cohort of HIV-infected patients hospitalized with severe sepsis in Uganda-high frequency, low clinical suspicion and derivation of a clinical prediction score. *PLoS One*;8(8):e70305.
86. Wald A, Timmler B, **Magaret A**, Warren T, Tyring S, Johnston C, Kriesel J, Fife K, Galitz L, Stoelben S, Huang ML, Selke S, Stobernack, HP, Corey L, Ruebsamen-Schaeff H, Birkmann A. 2014. Helicase-primase inhibitor pritelivir for reduction of genital herpes simplex virus shedding. *NEJM*;370(3):201-10.
87. Aubert M, Boyle NM, Stone D, Stensland D, Huang ML, **Magaret A**, Galetto R, Rawlings DJ, Scharenberg AM, Jerome KR. 2014. In vitro inactivation of latent HSV by targeted mutagenesis using an HSV-specific homing endonuclease. *Molecular Therapy - Nucleic Acids*, 3, e146.
88. Gantt S, Cattamanchi A, Krantz E, **Magaret A**, Selke S, Kuntz S, Huang ML, Corey L, Wald A, Casper C. 2014. Reduced human herpesvirus-8 replication at the oropharyngeal mucosa associated with protease inhibitor-based antiretroviral therapy. *J Clin Vir*;60(2):127-132.
89. Sedlak RH, Cook L, Huang ML, **Magaret A**, Zerr DM, Boeckh M, Jerome JR. 2014. Identification of chromosomally integrated human herpesvirus 6 by droplet digital PCR. *Clin Chem*;60(5):765-722.
90. Johnston C, Zhu J, Jing L, Laing KJ, McClurkan CM, Klock A, Diem K, Stanaway K, Tronstein E, Kwok WW, Huang ML, Selke S, Fong Y, **Magaret A**, Koelle DM, Wald A,

- Corey L. 2014. Virologic and immunologic evidence of multifocal genital herpes simplex virus type 2 infection. *J Virol*;88(9):4921-4931.
91. Mitchell C, McLemore L, Westerberg K, Smythe K, Gardella C, Astonomo R, Mack M, **Magaret A**, Patton D, Agnew K, McElrath J, Hladik F, Eschenbach D. 2014. Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells. *J Infect Dis*;210(4):651-5.
 92. Chu H, Steinhoff MC, **Magaret A**, Zaman, Z, Roy E, Langdon G, Formica MA, Walsh EE, Englund J. 2014. Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. *J Infect Dis*;210(10):1582-9.
 93. Delaney S, Gardella G, Saracino M, **Magaret A**, Wald A. 2014. Seroprevalence of herpes simplex virus type 1 and 2 among pregnant women, 1989-2010. *JAMA*;312(7):746-8..
 94. Mark K, Spruance S, Kinghorn G, Sacks S, Slade H, Meng TC, Selke S, **Magaret A**, Wald A. 2014. Three phase III randomized controlled trials of topical resiquimod > 0.01% gel to reduce anogenital herpes recurrences. *Antimicrob Agents Chemother*;58(9):5016-23.
 95. Perti T, Nyati M, Gray G, DeBruyn G, Selke S, **Magaret A**, Huang ML, Velaphi S, Corey L and Wald A. 2014. Frequent genital HSV-2 shedding among women during labor in Soweto, South Africa. *Infect Dis Obstet Gyn*, Article ID 258291, 8 pages.
 96. Sedlak RM, Cook L, Cheng A, **Magaret A**, Jerome K. 2014. Clinical utility of droplet digital PCR for human cytomegalovirus. *J Clin Micro*;52(8):2844-8.
 97. Rajagopal S, **Magaret A**, Mugo N, Wald A. 2014. Incidence of herpes simplex virus type 2 infections in Africa: a systematic review. *Open Forum Inf Dis*;1(2):ofu043.
 98. Melvin AJ, Mohan KM, Schiffer JT, Drolette LM, **Magaret A**, Wald A. 2015. Plasma and CSF herpes simplex virus levels at diagnosis and outcome of neonatal infection. *J Ped*;166(4):827-33.
 99. Looker KJ, **Magaret AS**, Turner KME, Vickerman P, Gottlieb SL, Newman LM. 2015. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. *PLOS One*;10(1):e114989.
 100. Laing KJ, Russell RM, Dong L, Schmid DS, Stern M, **Magaret A**, Haas JG, Johnston C, Wald A, Koelle DM. 2015. Zoster vaccination increases the breadth of CD4+ Tcells responsive to varicella zoster virus. *J Infect Dis*;212(7):1022-31.
 101. Bender RAB, Perti T, **Magaret AS**, Rajagopal S, Stevens CE, Huang ML, Selke S, Johnston C, MARRAZZO J, Wald A. 2015. Oral and gel tenofovir for genital HSV-2 shedding in immunocompetent women: a double-blind randomized cross-over trial. *J Infect Dis*;212(12):1949-56.
 102. Mujugira A, Huang ML, Selke S, Drolette L, **Magaret A**, Wald A. 2015. High rate of β -globin DNA detection validates self-sampling in HSV shedding studies. *STD*;42(12):705-709.
 103. Boyle, N, **Magaret A**, Stednick Z, Morrison A, Buler-Wu S, Zerr D, Rogers K, Podczervinski S, Cheng A, Wald A, Pergam S. 2015. Evaluating risk factors for *Clostridium difficile* infection in adult and pediatric hematopoietic cell transplant recipients. *Anti Resist Inf Control*;4:41.

104. Looker KJ, **Magaret AS**, May MT, Turner KME, Vickerman P, Gottlieb SL, Newman LM. 2015. Global and regional estimates of prevalent and incident herpes simplex virus type I infections in 2012. *Plos One*;10(10):e0140765.
105. Diem K, **Magaret A**, Klock A, Jin L, Zhu J, Corey L. 2015. Image analysis for accurately counting CD4+ and CD8+ T cells in human tissue. *J Virol Methods*;222:117-21.
106. **Magaret AS**, Angus DC, Adhikari NKJ, Banura P, Kissoon N, Lawler J, Jacob ST. 2016. Design and of a multi-arm randomized clinical trial with no control arm. *Contemp Clin Trials*;46:12-17.
107. Zaniello B, Huang ML, Cheng A, Selke S, Wald A, Jerome KR, **Magaret AS**. 2016. Consistent viral DNA quantification after prolonged storage at ambient temperature. *J Virol Methods*;228:91-94.
108. **Magaret AS**, Mujugira A, Hughes J, Lingappa J, Bukusi EA, DeBruyn G, Delaney-Moretwe S, Fife KH, Gray GE, Kapiga S, Karita E, Mugo NR, Rees H, Ronald A, Vwalika B, Were E, Celum C, Wald A for the Partners in Prevention HSV/HIV Transmission Study Team. 2016. Effect of condom use on per-act HSV-2 transmission risk in HIV-1, HSV-2-discordant couples. *Clin Infect Dis*;62(4):456-61.
109. Hall-Sedlak R, Liang S, Niyonzima N, DeSilva-Feelixge HS, Roychoudhury P, Weber ND, Boissel S, Scharenberg, AM, Cheng A, **Magaret A**, Bumgarner R, Stone D, Jerome KR. 2016. Digital detection of endonuclease mediated gene disruption in the HIV provirus. *Scientific reports*;6:20064.
110. Bender Ignacio RA, Goldman JD, **Magaret AS**, Selke S, Huang ML, Gantt S, Johnston C, Phipps WT, Schiffer JT, Zuckerman RA, McClelland RS, Celum C, Corey L, Wald A, Casper C. 2016. Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons. *Infect Agent Cancer*;11:7.
111. Hill, JA, Hall-Sedlak R, **Magaret A**, Huang ML, Zerr DM, Jerome KR, Boeckh M. 2016. Efficient identification of inherited chromosomally integrated human herpesvirus 6. *J Clin Virol*;77:71-6.
112. Schiffer JR, Swan DA, **Magaret A**, Corey L, Wald A, Ossig J, Ruebsamen-Schaeff H, Stoelben S, Timmler B, Zimmermann H, Melhem MR, Van Wart SA, Rubino CM, Birkmann A. 2016. Mathematical models of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes. *Sci Trans Med*;8(324);324ra15.
113. Chu HY, Katz J, Tielsch J, Khatry SK, LeClerq S, **Magaret A**, Kuypers J, Steinhoff MC, Englund JA. 2016. Clinical presentation and birth outcomes associated with respiratory syncytial virus infection in pregnancy. *PLOS One*;11(3):e0152015.
114. Milman, N, Zhu J, Johnston C, Cheng A, **Magaret A**, Koelle DM, Huang ML, Jin L, Klock A, Layton E, Corey L. 2016. In situ detection of regulatory T cells in human genital HSV-2 reactivation and their influence on spontaneous HSV-2 reactivation. *J Infect Dis*;214(1):23-31.
115. Schiffer JT, Swan DA, **Magaret A**, Schacker T, Wald A, Corey L. 2016. Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons is Due to Poor Immunologic Control in Ganglia and Genital Mucosa. *PLOS One*;11(6):e0155124.
116. Chu, HY, Katz J, Tielsch J, Khatry SK, Shrestha L, LeClerq SC, **Magaret A**, Kuypers J, Steinhoff M, Englund JA. 2016. Respiratory Syncytial Virus Infection in Infants in Rural Nepal. *Journal of Infection*;73(2):145-54.

117. Oseso L, **Magaret AS**, Jerome KR, Fox J, Wald A. 2016. Attitudes and willingness to assume risk of experimental therapy to eradicate genital herpes simplex virus infection. *Sex Trans Dis*;43(9):566-71.
118. Ramchandani M, Kong M, Tronstein E, Selke S, Mikhaylova A, **Magaret A**, Huang ML, Johnston C, Corey L, Wald A. 2016. Herpes simplex virus type 1 shedding in tears, and nasal and oral mucosa of healthy adults. *Sex Trans Dis*;43(12):756-760.
119. Aubert M, Madde EA, Loprieno M, DeSilva Feelixge HS, Stensland L, Huang ML, Greninger AL, Roychoudhury P, Niyonzima N, Nguyen T, **Magaret A**, Galetto R, Stone D, Jerome KR. 2016. In vitro disruption of latent HSV by designer endonuclease therapy. *JCI Insight*;1(14):e88468.
120. Manguro G, Masese LN, Deya R, **Magaret A**, Wald A, McClelland RS, Graham SM. Genital HSV shedding among Kenyan women initiating antiretroviral therapy. 2016. *PLoS One*;11(9):e0163541.
121. **Magaret A**, Dong L, John M, Mallal SA, James I, Warren T, Gaudieri S, Koelle DM, Wald A. 2016. HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions. *Nature: Genes & Immunity*;17(7):412-418.
122. Wald A, Timmler B, **Magaret A**, Warren T, Tyring S, Johnston C, Fife K, Selke S, Huang ML, Stobernack HP, Zimmermann H, Corey L, Birkmann A, Ruebsamen-Schaeff H. 2016. Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrence: a randomized clinical trial. *JAMA*;316(23):2495-2503.
123. Newman LP, Njoroge A, **Magaret A**, Chohan BH, Vitomea VW, Wald A, Gorstein J, Overbaugh J, Wamalwa D, Maleche-Obimbo E, Nduati R, Farquhar C. 2017. Sustained responses to measles revaccination at 24 months in HIV-infected children on antiretroviral therapy in Kenya. *Ped Inf Dis*;doi: 10.1097.
124. Posavad CM, Zhao L, Dong L, Jin L, Stevens CE, **Magaret AS**, Johnston C, Wald A, Zhu J, Corey L, Koelle DM. 2017. Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract. *Mucosal Immunology*;10(5):1259-126.
125. Looker KJ, **Magaret AS**, May MT, Turner KME, Vickerman P, Newman LM, Gottlieb SL. 2017. First estimates of the global and regional incidence of neonatal herpes infection. *Lancet Global Health*;5(3):e300-e309.
126. Bernstein D, Wald A, Warren T, Fife K, Tyring S, Lee P, Van Wagoner N, **Magaret A**, Flechtner JB, Tasker S, Chan J, Morris A, Hetherington S. 2017. Therapeutic vaccine for genital herpes simplex virus-2 infection: findings from a randomized trial. *J Infect Dis*;215(6):856-864.
127. Lovelace ES, Maurice NJ, Miller HW, Slichter CK, Harrington R, **Magaret A**, Prlic M, DeRosa S, Polyak SJ. 2017. Silimarin suppresses basal and stimulus-induced activation, exhaustion, differentiation, and inflammatory markers in primary human immune cells. *Plos One*;12(2):e0171139.
128. Saifee NH, Evans HL, **Magaret AS**, Hess JR, Delaney M, O'Keefe GE, Pham TN, Foy H, Bulger E, Pagano MB. 2017. Outcomes in necrotizing soft-tissue infections treated with therapeutic plasma exchange. *Transfusion*;57(6):1407-1413.

129. Koelle DM, Norbert P, Fitzgibbon MP, Russell RM, Greninger AL, Huang ML, Stensland L, Jing L, **Magaret AS**, Diem K, Selke S, Xie H, Celum C, Lingappa JR, Jerome KR, Wald A, Johnston C. 2017. Worldwide circulation of HSV-2 x HSV-1 recombinant strains. *Sci Rep*;7:44084.
130. Philpott EK, Englund JA, Katz J, Tielsch J, Khattry S, LeClerq SC, Shrestha L, Kuypers J, **Magaret AS**, Steinhoff MC, Chu HY. 2017. Febrile rhinovirus illness during pregnancy is associated with low birthweight in Nepal. *Open Forum Infectious Diseases*;4(2):ofx073.
131. Lenahan JL, Englund JA, Katz J, Kuypers J, Wald A, **Magaret A**, Tielsch JM, Khattry SK, LeClerq SC, Shrestha L, Steinhoff MC, Chu HY. 2017. Clinical presentation of human metapneumovirus and other respiratory infections during pregnancy and impact on birth outcomes. *Emerg Inf Dis*;23(8):1341-1349.
132. Yager JE, **Magaret AS**, Kuntz SR, Selke S, Huang ML, Corey L, Casper C, Wald A. Valganciclovir for the suppression of Epstein-Barr virus replication. *J Infect Dis*;216(2):198-202.
133. Hill JA, Hall-Sedlak R, **Magaret A**, Mikhaylova A, Huang ML, Jerome KR, Zerr DM, Boeckh M. 2017. Outcomes of hematopoietic cell transplantation using donors or recipients with inherited chromosomally integrated HHV-6. *Blood*;130(8):1062-1069.
134. Hensel M, Peng T, Cheng A, DeRosa S, Wald A, Laing K, Jing L, Dong L, **Magaret A**, Koelle DM. 2017. Selective expression of CCR10 and CXCR3 by circulating human HSV-specific CD8 T-cells. *J Virol*;91(19): e00810-17.
135. Johnston C, **Magaret A**, Roychoudury P, Greninger AL, Cheng A, Diem K, Fitzgibbon MP, Huang ML, Selke S, Lingappa JR, Celum C, Jerome KR, Koelle DM, Wald A. 2017. Highly conserved intragenic HSV-2 sequences: results from next-generation sequencing of HSV-2 UL and US regions from HSV-2 DNA swabs collected from 3 continents. *Virology*;510:90-98.
136. Chu HY, Tielsch J, Katz J, **Magaret AS**, Khattry SK, LeClerq SC, Shrestha L, Kuypers J, Steinhoff MC, Englund JA. 2017. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal. *J Clin Virol*;95:90-95.
137. Agyemang EA, Le QA, Warren T, **Magaret AS**, Selke S, Johnston C, Wald A. 2017. Performance of commercial enzyme-linked immunosorbent assays (ELISA) for diagnosis of HSV-1 and HSV-2 infection in a clinical setting. *STD*;44(12):763-767.
138. Johnston C, **Magaret A**, Roychoudhury P, Greninger AL, Reeves D, Schiffer J, Jerome KR, Sather C, Diem K, Lingappa JR, Celum C, Koelle DM, Wald A. 2017. Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the USA, Peru, and eight countries in sub-Saharan Africa: a nested cross-sectional viral genotyping study. *Plos Med*;14(12):e1002475.
139. Stankiewicz KH, Moss NJ, Laschansky E, Drolett L, **Magaret AS**, Selke S, Gardella C, Wald A. 2017. Invasive obstetric procedures and cesarean sections in women with herpes simplex virus status during pregnancy. *Open Forum Inf Dis*;4(4):ofx248.
140. Parker M, Han Z, Abu-Haydar E, Matsiko E, **Magaret A**, Iyakaremye D, Tuyisenge L, Lyambabaje A. 2018. An evaluation of hemoglobin measurement tools and their inaccuracies when screening for child anemia in Rwanda. *Plos One*;13(1):e0187663.

141. Reeves DB, **Magaret AS**, Greninger A, Johnston C, Schiffer JT. 2018. Estimating superinfection prevalence from limited datasets. *J Royal Society Interface*;15 (139): 20170968.
142. Lee CS, Yee AY, Akileswaran L, Stroman D, Najafi-Tagol K, Kleibocker S, Chodosh J, **Magaret A**, Wald A. 2018. Determinants of outcomes of adenoviral keratoconjunctivitis. *Ophthalmology*;125(9):1344-1353.
143. Ramchandani M, Selke S, **Magaret AS**, Barnum G, Huang ML, Corey L, Wald A. 2018. Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition. *Sex Trans Inf*;94(8):568-570.
144. Agyemang EA, **Magaret AS**, Selke S, Johnston C, Corey L, Wald A. 2018. HSV shedding rate: surrogate outcome for genital herpes recurrence frequency and lesion rates, and phase II clinical trials endpoint for evaluating efficacy of antivirals. *J Infect Dis*;218(11):1691-1699.
145. Ford ES, **Magaret AS**, Spak CW, Selke S, Kuntz S, Corey L, Wald A. 2018. Increase in HSV shedding at initiation of antiretroviral therapy (ART) and decrease in shedding over time on ART in HIV and HSV-2 infected persons. *AIDS*;32(17):2525-2531.
146. Mugo N, Eckert L, **Magaret AS**, Cheng A, Lawrence Mwaniki, Ngure K, Celum C, baeten JM, Galloway D, Wamalwa D, Wald A. 2018. Quadrivalent HPV vaccine in HIV-infected early adolescent girls and boys in Kenya: month 7 and 12 post vaccine immunogenicity and correlation with immune status. *Vaccine*;36(46):7025-7032.
147. Dalmat RR, Makhsous N, Pepper G, Magaret A, Jerome KR, Wald A, Greninger AL. 2018. Limited marginal utility of deep sequencing for HIV drug resistance testing in the age of integrase inhibitors. *J Clin Micro*;56(12):e01443-18.
148. Mazur NI, Horsley N, Englund JA, Nederend M, **Magaret A**, Kumar A, Jacobino SR, de Haan CAM, Khattry SK, LeClerq SC, Steinhoff MC, Tielsch JM, Katz J, Graham BS, Bont LJ, Leusen JHW, Chu HY. 2019. Breast milk prefusion F IgG as a correlate of protection against respiratory syncytial virus acute respiratory illness. *J Infect Dis*;219(1):59-67. PMID: 30107412
149. Micks EA, Son H, **Magaret A**, Selke S, Johnston C, Wald A. 2019. The effect of hormonal contraception and menstrual cycle timing on genital herpes simplex virus-2 shedding and lesions. *Sex Trans Dis*;46(1):58-62. PMID: 30148758
150. Ramchandani MS, Jing L, Russell RM, **Magaret A**, Selke E, Cheng A, Huang ML, Strachan E, Wald A, Koelle DM. 2019. Viral genetics modulate orolabial HSV-1 shedding in humans. *J Infect Dis*;219(7):1058-1066. PMID: 30383234
151. Beieler A, **Magaret A**, Zhou Y, Wald A, Schleyer A, Dhanireddy S. 2019. Outpatient antibiotic parenteral therapy (OPAT) in vulnerable populations - persons who inject drugs and the homeless. *J Hosp Med*;14(2):105-109. PMID: 30785418
152. Azenkot T, Zaniello Bn, Green ML, Selke S, Huang ML, **Magaret A**, Wald A, Johnston C. 2019. Cytomegalovirus shedding from breastmilk and mucosal sites in healthy post-partum women: a pilot study. *J Med Virol*;91(5):894-898. PMID: 30578684
153. Karita HS, Hauge K, **Magaret AS**, Mao C, Schouten J, Grieco V, Xi LF, Galloway D, Madeleine M, Wald A. 2019. Effect of human papillomavirus vaccine to interrupt recurrence of vulvar and anal neoplasia (VIVA trial): a trial protocol. *JAMA Open Network*; 2(4):e190819. PMID: 30977845

154. Boonyaratanakornkit J, Ekici S, **Magaret A**, Gustafson K, Scott E, Haglund M, Kuypers J, Pergamit R, Lynch J, Chu HY. 2019. Respiratory syncytial virus infection in the homeless population. *Emerging Inf Dis*;25(7):1408-1411. PMID: 31211675
155. Dabestani, N, Katz D, Dombrowski J, **Magaret A**, Wald A, Johnston C. 2019. Time trends in first-episode genital herpes simplex virus infections in an urban sexually transmitted disease clinic. *Sex Trans Dis*;46(12):795-800. PMID: 31764767
156. Newman KL, Gustafson K, Englund JA, **Magaret A**, Khatri S, LeClerq SC, Tielsch JM, Katz J, Chu HY. 2019. Effect of diarrheal disease during pregnancy on adverse birth outcomes in Nepal. *Open Forum Inf Dis*;6(2):UNSP ofz011. PMID: 30793004
157. Boonyaratanakornkit J, Englund JA, **Magaret AS**, Bu Y, Tielsch JM, Khatri SK, Katz J, Kuypers J, Shrestha L, LeClerq SC, Steinhoff MC, Chu HY. 2020. Primary and repeated respiratory viral infections among infants in rural Nepal. *J Ped Inf Dis*;9(1):21-29. PMID: 30423150
158. Stankiewicz Karita HC, **Magaret A**, Huang ML, Jerome KR, Feng Q, Wald A. 2020. Quantitative oral HPV16 and HPV18 detection in persons attending dental clinics. *Sex Trans Dis*;47(2):100-104. PMID: 31804297
159. Scott EM, **Magaret AS**, Kuypers J, Tielsch JM, Katz J, Khatri SK, Stewart L, Shrestha L, LeClerq SC, Englund JA, Chu HY. 2020. Risk factors and dynamics of household clusters of respiratory viruses in rural Nepal. *Epidemiol Infect*;147:e288. PMID: 31607271
160. Taub RL, Ellis SA, Neal-Perry G, **Magaret AS**, Prager SW, Micks EA. 2020. The effect of testosterone on ovulatory function in transmasculine individuals. *Am J Obstet & Gyn*; S0002-9378(20)30134-4. PMID: 32044312
161. **Magaret AS**, Mayer-Hamblett N, VanDevanter D. 2020. Expanding access to CFTR modulators for rare mutations: the utility of n-of-1 trials. *J Cystic Fibrosis*;19(1):1-2. PMID: 31831338
162. **Magaret AS**, Warden M, Heltshe S, Simon N, Mayer-Hamblett N. 2020. Real-world evidence in cystic fibrosis modulator development: establishing a path forward. *J Cystic Fibrosis*;19(3):e11-e12. PMID: 32291159
163. Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, Durmowicz AG, Ratjen F, Konstan MW, Pearson K, Bell SC, Clancy JP, Taylor-Cousar JL, De Boeck K, Donaldson SH, Downey DG, Flume PA, Drevinek P, Goss CH, Fajac I, **Magaret AS**, Quon BS, Singleton SM, VanDalfsen JM, Retsch-Bogart GZ. 2020. Building global development strategies for CF therapeutics during a transitional CFTR modulator era. 2020. *J Cystic Fibrosis*;19(5):677-687. PMID: 32522463
164. **Magaret AS**, Jacob ST, Halloran ME, Guthrie KA, Magaret CA, Johnston C, Simon NR, Wald A. 2020. Multiple-arm, adaptively randomized trials are advantageous for comparing COVID-19 interventions. *Ann Intern Med*;173(7):576-577. PMID: 32525715
165. Yuh T, Micheni M, Selke S, Oluoch L, Kiptinness C, **Magaret A**, Chohan B, Ngure K, Wald A, Mugo NR, Roxby AC. 2020. Sexually transmitted infections among Kenyan adolescent girls and young women with limited sexual experience. *Front Public Health*;8:303. PMID: 32766197
166. Stankiewicz Karita HS, Waterboer T, **Magaret A**, Doody DR, Pawlita M, Brenner N, Wald A, Madeleine MM. 2020 Humoral response to HPV16 proteins in persons with anal

- high-grade squamous intraepithelial lesion or anal cancer. *Canc Epi Biom & Prev*;29(11):2255-2260. PMID: 32883662
167. **Magaret AS**, Salerno, J, Deen JF, Kloster M, Mayer-Hamblett N, Ramsey BW, Nichols DP. 2021. Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis. *J Cyst Fib*;20(2):e16-e18. PMID: 33246911
168. Peng T, Phasouk K, Sodroski CN, Sun S, Hwangbo Y, Layton E, Jin L, Klock A, **Magaret A**, Li A, Huang ML, Johnston C, Jerome KR, Koelle DM, Wald A, Knipe DM, Corey L, Zhu J. 2021. Tissue-resident CD8⁺ T-cells activate innate antiviral restriction in neighboring epithelial cells. *Frontiers in Immunology*; 12:735643. PMID: 34552595
169. **Magaret AS**, Warden M, Simon N, Heltshe S, Retsch-Bogart GZ, Ramsey BW, Mayer-Hamblett N. 2022. A new path for CF clinical trials through the use of historical controls. *J Cyst Fib*; 21(2):293-299. PMID: 34879997
170. Jain R, **Magaret A**, Vu Phuong, VanDalfsen JM, Keller A, Wilson A, Putman, M, Mayer-Hamblett N, Esther C, Taylor-Cousar JL. 2022. Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS clinical trial study design. *BMJ Open Respir Res*; 9(1):e001289. PMID: 35710144
171. Rosenfeld M, Ostrenga J, Cromwell EA, **Magaret A**, Szczesniak R, Fink A, Schechter MS, Faro A, Ren CL, Morgan W, Sanders DB. 2022. Real-world associations of U.S. cystic fibrosis newborn screening programs with nutritional and pulmonary outcomes. *JAMA Peds*; 176(10):990-999. PMID: 35913705
172. Johnston C, **Magaret A**, Son H, Stern M, Rathbun M, Renner J, Szpara M, Gunby S, Ott M, Jing L, Campbell VL, Huang ML, Selke S, Jerome KR, Koelle DM, Wald A. 2022. Viral shedding one year following first-episode genital HSV-1 infection. *JAMA*; 328(17):1730-1739. PMID: 36272098.
173. Babu TM, Srinivasan S, **Magaret A**, Proll S, Karita HS, Wallis JM, Selke S, Varon D, Pholsena T, Fredricks D, Marrazzo J, Wald A, Johnston C. 2023. Genital herpes simplex virus type 2 suppression with valacyclovir is not associated with changes in nugent score or absolute abundance of key vaginal bacteria. *Open Forum Inf Dis*;10(3):ofado99. PMID: 36949872.
174. Thornton CS, **Magaret AS**, Carmody LA, Kalikin LM, Simon RH, LiPuma JJ, Caverly LJ. 2023. Quantifying variation in home spirometry in people with cystic fibrosis during baseline health, and associations with clinical outcomes. *J Cystic Fibrosis*, S1569-1993(23)00141-8. PMID: 37244842.
175. Godfrey EM, Schwartz MR, Hinckley Stukovsky KD, Woodward D, **Magaret AS**, Aitken ML. 2023. Electronic survey piloting process as a model for developing and testing past contraceptive use and pregnancy history: Cystic fibrosis case study. *JMIR Form Res*, 7:e46395. PMID: 37463015.
176. Patil R, **Magaret AS**, Jain R, Taylor-Cousar JL, Hughan KS, Kazmerski TM. 2023. Factors associated with pubertal growth outcomes in cystic fibrosis: early growth and puberty in CF. *J Cystic Fibrosis*, S1569-1993(23)01660-0. PMID: 37981481.
177. Ford ES, Li A, Laing KJ, Dong L, Diem K, Jing L, Basu K, Ott M, Tartaglia J, Gurunathan S, Reid JL, Ecsedi M, Chapuis AG, Huang ML, **Magaret AS**, Johnston C, Zhu J, Koelle DM, Corey L. 2024. Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine. *JCI Insight*; in press. PMID: 38352384.

178. Bihler H, Sivachenko A, Millen L, Bhatt P, Patel AT, Chin J, Bailey V, Musisi I, LaPan A, Allaire NE, Conte J, Simon NR, **Magaret AS**, Raraigh KS, Cutting GR, Skach WR, Bridges RJ, Thomas PJ, Mense M. 2024. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis. *JCF*; S1569-1993(24)00021-3. PMID: 38388235.
179. Warden M, Heltshe SL, Simon N, Mooney SJ, Mayer-Hamblett N, **Magaret AS**. 2024. Statistical approaches for the integration of external controls in a cystic fibrosis clinical trial: a simulation and an application. *Am J Epi*; in press.
180. **Magaret AS**, Graham E, Caverly LJ, Cromwell EA, Paynter A, Rosenfeld M, Thornton CS, Goss CH. Impact of day-to-day variation in FEV₁ on measures of change: a conceptual description. *JCF*; in press.
181. Rayas M, Mbogo B, Heltshe S, **Magaret AS**, Daley T. Association of race and ethnicity with development of cystic fibrosis-related diabetes. *JCF*; in press.
182. Graham E, Heltshe S, **Magaret AS**. Baseline-dependent improvement in CF studies, plausibility of bias. *Contemporary Clinical Trials Communications*; in press.

b) Collaborative Authorship (none)

c) MedEdPortal or other Peer Reviewed Curricula (none)

d) Book Chapters

Janes H and **Magaret A**. (authors contributed equally) Chapter 2, Statistical evaluation of diagnostic tests. In: Lennette's laboratory diagnosis of viral infections, 4th ed, edited by Jerome, KR. Informa Healthcare, New York, 2010.

e) Published Books, Videos, Software

1. R packages *estabphi* and *formbbinom* are available with this article: Sample size for a binomial proportion with autocorrelation. *Stat Comm Infect Dis*;3(1):Article 8. DOI: 10.2202/1948-4690.1036
2. R code for clinical trial simulation is available with this article: Design and of a multi-arm randomized clinical trial with no control arm. *Contemp Clin Trials*, 46:12-17.

f) Other Publications

1. **Magaret A**. 2016. Models for HSV shedding must account for two levels of overdispersion. University of Washington Biostatistics working paper series, #410. <http://biostats.bepress.com/uwbiostat/paper410/>
2. **Magaret AS**, Wald A. 2017. Autism link to herpes simplex virus 2 antibody in pregnancy likely to be spurious. *mSphere*, 2:e00106-17.

g) Manuscripts Submitted

1. West NE, Konstan MW, Flume PA, VanDevanter DR, **Magaret A** et al. Cannabinoid receptor 2 agonist, Lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosis. Submitted.

h) Abstracts (last 5 years)

1. Johnston C, **Magaret A**, Wald A. Natural history of genital and oral herpes simplex virus-1 (HSV-1) shedding after first episode genital HSV-1 infection. International Society for Sexually Transmitted Diseases Research, Vancouver, BC, CA, 2019.
2. Karita HS, **Magaret A**, Feng Q, Wald A. Quantitative oral HPV16 and HPV18 detection in patients attending dental clinics. International Society for Sexually Transmitted Diseases Research, Vancouver, BC, CA, 2019.
3. Warden M, **Magaret AS**, Simon N, Heltshe S, Retsch-Bogart GZ, Ramsey BW, Mayer-Hamblett N. A new path for CF clinical trials through the use of historical controls. NACFC, (online) 2021.
4. Warden M, **Magaret AS**, Mooney S, Simon N, Mayer-Hamblett N. Evaluating analytic methods for trial designs that utilize historical controls in the context of cystic fibrosis. Society for Epidemiologic Research, Chicago, IL, 2022.
5. Patil R, **Magaret A**, Jain R, Taylor-Cousar JL, Stalvey M, Kazmerski TM. Impact of early growth trajectories and CFTR modulator therapy on puberty in cystic fibrosis. NACFC, Philadelphia, PA, 2022.
6. Godfrey EM, Hinckley Stukovsky K, Ruben M, Rattliff B, **Magaret A**, Aitken ML. Contraception and pregnancy in a cohort of women with cystic fibrosis in the era of Trikafta. NACFC, Philadelphia, PA, 2022.
7. Thornton C, **Magaret A**, Carmody J, Kalikin L, Simon R, LiPuma R. Use of daily home spirometry to predict clinical outcomes in persons with cystic fibrosis. NACFC, Philadelphia, PA, 2022.
8. Warden M, **Magaret AS**, Mooney S, Simon N, Mayer-Hamblett N. Approaches that use historical controls to meet modern needs in cystic fibrosis trials. NACFC, Philadelphia, PA, 2022.
9. Milinic T, **Magaret AS**, Brown CE, Bayomy OF, Siddhartha G, Ramos KJ, Goss C. Racial and Ethnic Representation in Clinical Trials in the CF Therapeutics Development Network. American Thoracic Society, Washington D.C., 2023.
10. Polineni EC, Milinic T, **Magaret A**, Goss C, Clancy JP, Mayer-Hamblett N. US research participation and demographics in people with CF who are ineligible for CFTR modulators show an imminent need for trial engagement strategies. NACFC, Phoenix, AZ, 2023.
11. Mody S, Ruben M, **Magaret AS**, Fiastro A, Hsu C, Roe AH, Taylor-Cousar JL, Kazmerski T, Uluer A, West N, Jain R, Walker P, Bray LA, Godfrey EM. Venous thromboembolism among people with cystic fibrosis using hormonal contraceptives. NACFC, Boston, MA, 2024.
12. Godfrey EM, **Magaret A**, Hsu C, Walker P, Schwind E, Roe AH, Uluer A, West N, Taylor-Cousar JL, Bray L-A, Mody S, Kazmerski T, Jain R, Aitken ML. Contraceptive use and pregnancy trends in the era of highly effective modulator therapy. NACFC, Boston, MA, 2024.
13. Martiniano SL, **Magaret A**, Lovell VL, Keck A, Vandalsen JM, Heltshe SL, Midamba N, Chapdu C, Nick JA. Reduction in positive cultures for NTM and pulmonary disease in people with CF in the era of highly effective modulator therapy among participants in the longitudinal PREDICT study. NACFC, Boston, MA, 2024.
14. Jain R, Emerman I, Odem-Davis K, Cameron N, Keller A, Wilson A, Putman M, **Magaret A**, Taylor-Cousar JL. Maternal and fetal outcomes in the era of CFTR modulators (MAYFLOWERS) study: interim results. NACFC, Boston, MA, 2024.
15. Mbogo B, **Magaret AS**, Nichols D, Heltshe SL, Flume P, Goss CH. Persons with worse psychological status at STOP-2 enrollment have increased incidence of adverse experiences. NACFC, Boston, MA, 2024.

18. Invited* lectures and oral presentations**Regional**

1. May 2004. Invited speaker*. Issues in the timing of data collection for estimating treatment effects in randomized clinical trials. Seminar, Department of Biostatistics, UW, Seattle.
2. Oct 2004. Invited speaker*. HSV Research and issues in shedding observation intervals. Seminar, Department of Biostatistics, UW, Seattle.

3. Dec 2044. Invited speaker*. Three myths about statistics, or how to alienate great blue herons. Program in Infectious Diseases / Division of Virology Annual Meeting, FHCRC / UW, Seattle.
4. Feb 2005. Invited speaker*. Accuracy of HSV DNA detection by PCR. Program in Infectious Diseases / Division of Virology Research Conference, FHCRC / UW, Seattle.
5. July 2005. Invited speaker*. Statistical sampler: the low-fat smorgasbord approach to equations. Program in Infectious Diseases / Division of Virology Research Conference, FHCRC / UW, Seattle.
6. Sept 2006. Invited speaker*. Empirical versus parametric validation of discrete proportional hazards models. Program in Biostatistics seminar, Hutchinson Cancer Center, Seattle.
7. April 2007. Invited speaker*. Evidence of host genetic differences in HSV disease severity. Program in Infectious Diseases / Division of Virology Research Conference, FHCRC / UW, Seattle.
8. July 2007. Accepted presentation. Risk of subject-level misclassification in studies of herpes simplex virus and the usefulness of the term "shedder". International Society for Sexually Transmitted Diseases Research, Seattle.
9. March 2008. Invited speaker*. Is "shedder" a useful label in virus research? Crafting a message regarding the dichotomization of rates into "none" versus "some". SCHARP Statistical Sciences Brown Bag, FHCRC, Seattle.
10. March 2008. Invited speaker*. Beyond ROC Curves: Recent Statistical Advances in the Evaluation of Diagnostic and Prognostic Tests. Grand Rounds, Department of Laboratory Medicine, UW.
11. April 2009. Invited speaker*. "How many 'shedders' does it take to show my intervention works?" OR Absurdly-phrased study design issues in HSV. Program in Infectious Diseases / Division of Virology Research Conference, FHCRC / UW, Seattle.
12. June 2010. Invited speaker*. Accurate sample size for HSV2 shedding studies and PIP ancillary study: higher incidence of death in the HIV-infected partner. Program in Infectious Diseases / Division of Virology Research Conference, FHCRC / UW, Seattle.
13. Jan 2012. Invited speaker*. Per-act infectivity of HSV-2, Vaccine and Infectious Diseases Division, FHCRC, Seattle.
14. Feb 2012. Invited speaker*. Accurate estimation of the efficacy of condoms in preventing HSV acquisition, Research Conference, Department of Laboratory Medicine, Seattle.
15. Oct 2012. Invited speaker*. Statistical methodology for assessment of viral shedding and associated study design considerations. Biostatistics faculty seminar, FHCRC, Seattle.
16. Oct 2012. Invited speaker*. Using validation subsets to alleviate bias in proportional hazards models when outcomes are mismeasured. Clinical trials affinity group seminar, FHCRC, Seattle.
17. Nov 2013. Invited speaker*. A Bayesian randomized clinical trial for treatment of sepsis. Clinical Trials Affinity Group seminar, FHCRC, Seattle.
18. March 2014. Invited speaker*. Multi-arm trials using adaptive design: increased efficiency without induced bias. Grand Rounds, Department of Laboratory Medicine, UW, Seattle.
19. Oct 2015. Invited speaker*. Love is an Open Sore: But HSV shedding may be a better outcome than lesions for evaluating herpes treatments. Vaccine and Infectious Diseases Division Seminar, FHCRC, Seattle.
20. Sept 2017. Invited speaker*. Detecting viral superinfection with limited samples, or how Dempster, Laird, & Rubin can slash your sequencing costs. Vaccine and Infectious Diseases Division Seminar, FHCRC, Seattle.
21. July 2019. Invited speaker*. Historic controls in clinical trials. Stat Net Training Program, Therapeutics Development Network, Seattle.
22. July 2019. Invited speaker*. Lederer AJRCCM editorial and causal inference. Stat Net Training Program, Therapeutics Development Network, Seattle.
23. July 2019. Invited speaker*. N-of-1 studies, oxymoron or useful tool? Epidemiology and Biostatistics Annual Workshop, Therapeutics Development Network Coordinating Center, Seattle.

24. Oct 2019. Invited speaker*. Commonly Used Outcome Measures for CF Trials and Related Statistical Issues. Clinical Research Scholars Program, Therapeutics Development Network Coordinating Center, Seattle.
25. Oct 2019. Invited speaker*. Data Archive and Registry. Clinical Research Scholars Program, Therapeutics Development Network Coordinating Center, Seattle.
26. Feb 2020. Invited speaker*. Use of historical controls to assess emerging interventions in cystic fibrosis: a comparison of methods. Clinical Trials Affinity Group, FHCRG, Seattle.
27. Jan 2021. Invited speaker*. Observational studies and causal inference. Stat Net Training Program, Therapeutics Development Network Coordinating Center, Seattle.

National

1. June 2001. Accepted presentation. Discrete proportional hazards model for uncertain outcomes. Presented at the Western North American Region Biometric Society Meeting, Burnaby, British Columbia.
2. March 2003. Accepted presentation. Incorporating outcome validation subsets and discrete proportional hazards models. Presented at the Eastern North American Region Biometric Society Meeting, Tampa, FL.
3. June 2009. Accepted presentation. Sample size for repeated-measures autocorrelated binomial distribution. Western North American Region of the International Biometric Society, Portland OR.
4. June 2010. Accepted presentation. Misspecification of parameters in repeated-measures autocorrelated beta-binomial distribution: application to design of viral shedding studies. Western North American Region of the International Biometric Society, Seattle.
5. August 2020. Invited speaker*. Use of historical controls to assess emerging interventions in cystic fibrosis: a comparison of methods and look forward. Joint Statistical Meetings, Virtual.

International

1. Jan 2006. Invited speaker*. Enrollment characteristics. Partners in Prevention Study Annual Investigator's Meeting. Cape Town, South Africa.
2. March 2007. Invited speaker*. Analysis of primary outcome and relevant data considerations. Partners in Prevention Study Annual Investigator's Meeting. Arusha, Tanzania.